Events & Presentations
Board of Directors
Historic Stock Lookup
Galectin Therapeutics Announces $10 Million Credit Line from Richard E. Uihlein Sufficient to Cover Expected Expenditures into 2019
December 19, 2017 | Press Release
2017 Corporate Update Presentation
December 14, 2017 | Presentation
Healio: NASH cirrhosis treatment successful in patients without esophageal varices
December 6, 2017 | News Article
Why did you choose to become the CEO of Galectin Therapeutics?
Are you conducting clinical trials with GR-MD-02? What results have you seen so far?
Can you give me a quick overview of Galectin Therapeutics and the opportunity it sees for GR-MD-02?
Why are the results of the GR-MD-02 psoriasis study so promising?
Why is the NASH-CX trial so important?
See all videos
Galectin Therapeutics, Inc.
Financial Tear Sheet
Filings & Reports
Stock price updates every 30 minutes.
Latest Corporate Presentation
Media Fact Sheet
© 2018 Galectin Therapeutics Inc. - All Rights Reserved
Compassionate Use Policy
Disclaimer: This site may contain